no code implementations • 29 Sep 2023 • Guillermo Lorenzo, Jon S. Heiselman, Michael A. Liss, Michael I. Miga, Hector Gomez, Thomas E. Yankeelov, Alessandro Reali, Thomas J. R. Hughes
We further show that coupling our tumor forecasts with this PCa risk classifier enables the early identification of PCa progression to higher-risk disease by more than one year.
no code implementations • 28 Aug 2023 • Guillermo Lorenzo, Syed Rakin Ahmed, David A. Hormuth II, Brenna Vaughn, Jayashree Kalpathy-Cramer, Luis Solorio, Thomas E. Yankeelov, Hector Gomez
Despite the remarkable advances in cancer diagnosis, treatment, and management that have occurred over the past decade, malignant tumors remain a major public health problem.
no code implementations • 8 Dec 2022 • Guillermo Lorenzo, Angela M. Jarrett, Christian T. Meyer, Vito Quaranta, Darren R. Tyson, Thomas E. Yankeelov
As longitudinal \textsl{in vivo} MRI data for model calibration is limited, we perform a sensitivity analysis to identify the model mechanisms driving the response to two NAC drug combinations: doxorubicin with cyclophosphamide, and paclitaxel with carboplatin.
no code implementations • 16 Nov 2022 • Stéphane Urcun, Guillermo Lorenzo, Davide Baroli, Pierre-Yves Rohan, Giuseppe Sciumè, Wafa Skalli, Vincent Lubrano, Stéphane P. A. Bordas
Mechanical phenomena in cancer have been studied in-depth over the last decades, and their clinical applications are starting to be understood.
no code implementations • 24 Feb 2021 • Guillermo Lorenzo, David A. Hormuth II, Angela M. Jarrett, Ernesto A. B. F. Lima, Shashank Subramanian, George Biros, J. Tinsley Oden, Thomas J. R. Hughes, Thomas E. Yankeelov
Current clinical decision-making in oncology relies on averages of large patient populations to both assess tumor status and treatment outcomes.